DC Bead® with doxorubicin
Improved efficacy vs conventional TACE, particularly in patients with advanced disease

“Of interest, the subgroup analyses conducted in patients with large (>5cm) or multinodular tumor have both confirmed significantly higher objective response rates in patients receiving DEB [DEBDOX®] compared with those treated with conventional TACE.”

Song MJ, Park CH, Kim JD et al., Eur J Gastroenterol Hepatol 23 (2011): 521-527


For more information on this article, scan here or visit: www.dcbeadbibliography.co.uk/Song_EJGH_2011

DC Bead® Important Safety Information:

Cautions: DC Bead and DC Bead®

DC Bead® should only be performed by a physician with appropriate interventional occlusion training in the region intended to be embolized

Do not infuse DC Bead® into normal arteries adjacent to the targeted lesion

Ensure that DC Bead® is an appropriate size for the intended vasculature

CAUTION: DC Bead® is not for systemic use and is not intended for systemic drug delivery. DC Bead® is intended for use in the local occlusion of tumor vascularity.

External catheter

Cautions: DC Bead and DC Bead®

Catheter should only be performed by a physician with appropriate interventional occlusion training in the region intended to be embolized

Do not infuse DC Bead® into normal arteries adjacent to the targeted lesion

Ensure that DC Bead® is an appropriate size for the intended vasculature

CAUTION: DC Bead® is not for systemic use and is not intended for systemic drug delivery. DC Bead® is intended for use in the local occlusion of tumor vascularity.

External catheter

Potential Complications: DC Bead and DC Bead®

Unintended reflux or passage of DC Bead®/DC Bead®® into normal arteries adjacent to the targeted lesion

Non-target embolization

Pulmonary embolization

Ischemic or congestive heart failure

Hypertension

Hypotension

Dysrhythmias

Pneumothorax

Pleural effusion

Hypocalcemia

Hypomagnesemia

Hypokalemia

Hypoglycemia

Hypothermia

Acute renal failure

Pulmonary embolization

Ischemic stroke or ischemic infarction

Wound or incisional infection

Neurological deficits including cranial nerve palsy

Cerebrovascular accident (CVA)

CT scans obtained 1 month after treatment with DEB (e and f) show two hypervascular tumors. Angiography (c and d) confirms the presence of two nodular-type lesions consistent with HCC. On CT scans obtained 1 month after treatment with DEB (e and f), both tumors fail to show contrast uptake, suggesting CR according to modified Response Evaluation Criteria in Solid Tumors.
**DEBDOX®**: Delivering the standard of care in intermediate HCC

**Survival benefit confirmed with DC Bead®**
Survival of Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization (TACE) using DC Bead®:

For more information, scan here or visit: www.dcbeadbibliography.co.uk/Burrel_Hepatology_2012

**Sustained drug release from DC Bead® confirmed by histological explant data**

For more information, scan here or visit: www.dcbeadbibliography.co.uk/Namur_Hepatology_2011

**Improved efficacy vs conventional TACE, particularly in patients with advanced disease**

For more information, scan here or visit: www.dcbeadbibliography.co.uk/Song_EJGH_2011

**DEBDOX® technical recommendations**

For more information, scan here or visit: www.dcbeadbibliography.co.uk/Lencioni_CVIR_2011

**DEBDOX® with sorafenib is well tolerated, with excellent disease control**

For more information, scan here or visit: www.dcbeadbibliography.co.uk/Pawlik_JCO_2011

**PRECISION V: Improved tolerability & efficacy in more challenging HCC patients**

For more information, scan here or visit: www.dcbeadbibliography.co.uk/Lammer_CVIR_2010

**Improved outcomes over bland embolisation**

For more information, scan here or visit: www.dcbeadbibliography.co.uk/Malagari_CVIR_2010

**Superior pharmacokinetic profile**

For more information, scan here or visit: www.dcbeadbibliography.co.uk/Varela_Hepatology_2007

**Ordering Information:**

<table>
<thead>
<tr>
<th>Product Name</th>
<th>DC Bead®</th>
<th>DC Bead</th>
</tr>
</thead>
<tbody>
<tr>
<td>Label Colour and Size</td>
<td>70-150µm</td>
<td>100-300µm</td>
</tr>
<tr>
<td>Volume of Beads</td>
<td>2ml</td>
<td>2ml</td>
</tr>
<tr>
<td>Product Code</td>
<td>DC2V001</td>
<td>DC2V103</td>
</tr>
</tbody>
</table>

For more information, please contact:
Biocompatibles UK Limited
Chapman House, Farnham Business Park
Weydon Lane, Farnham, Surrey, GU9 8QL, UK
Tel: +44 (0)1252 732 732
Fax: +44 (0)1252 732 777
email: marketing@biocompatibles.com

Biocompatibles UK Ltd is a BTG International Group company. DC Bead and DC Bead® are manufactured by Biocompatibles UK Ltd, Chapman House, Farnham Business Park, Weydon Lane, Farnham, Surrey, GU9 8QL, UK. Biocompatibles UK Ltd is a BTG International Group company. DC Bead and DEBDOX® are registered trademarks and DC Bead® is a trademark of Biocompatibles UK Ltd. BTG and the BTG roundel logo are registered trademarks of BTG International Ltd. DC Bead is not currently cleared by the FDA for sale or distribution in the USA.

© Copyright 2012 Biocompatibles UK Ltd. ECD/055 (R) Rev 2.

The sizes of DC Bead® used in the studies listed may not be the same as are shown in this image. Link to study details for more information.